This page is part of the FHIR Specification (v1.1.0: STU 3 Ballot 1). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions

This is a frozen snapshot of the FHIR specification created for the purpose of balloting the GAO implementation Guide. It includes draft changes that may be part of the future DSTU 2.1 release but further change is expected. Readers should focus solely on the GAO implementation content, and FHIR DSTU 2 for other purposes.

1.25.4.1.1070 HL7 v3 Code System substanceAdminSubstitution

This code system (http://hl7.org/fhir/v3/substanceAdminSubstitution) is defined as part of HL7 v3.

Summary

Defining URL:

http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution

Name:

v3 Code System substanceAdminSubstitution

Definition:

Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.

OID:

(for OID based terminology systems)

System URL:

http://hl7.org/fhir/v3/substanceAdminSubstitution

System OID:

2.16.840.1.113883.5.1070

Source Resource

XML / JSON

This value set is not currently used

1.25.4.1.1070.1 Content Logical Definition

This value set has an inline code system http://hl7.org/fhir/v3/substanceAdminSubstitution, which defines the following codes:

Lvl	Code	Display	Definition
1	_ActSubstanceAdminSubstitutionCode	ActSubstanceAdminSubstitutionCode	Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.
2	E	equivalent	Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
3	EC	equivalent composition	Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril
4	BC	brand composition	Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven
4	G	generic composition	Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
3	TE	therapeutic alternative	Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet
4	TB	therapeutic brand	Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: Zantac for Tagamet
4	TG	therapeutic generic	Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: Ranitidine for cimetidine
2	F	formulary	Description: This substitution was performed or is permitted based on formulary guidelines.
2	N	none	No substitution occurred or is permitted.